Respiratory

Roche spends $8.3B for lung drug

Roche spends $8.3B for lung drug

By

Roche has beat out rumored competitors GlaxoSmithKline and Sanofi in a run-off to acquire California biotech InterMune.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

By

The FDA has approved Arnuity Ellipta for asthma.

GSK relaunches COPD.com

GSK relaunches COPD.com

By

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

By

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Endorsement could boost Pfizer vax

Endorsement could boost Pfizer vax

By

It could also eat into Merck's Pneumovax sales.

InterMune joins M&A fray

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.

Scotland's NICE dislikes GSK's Anoro

The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

By

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

GSK's first-quarter sales slide

GSK's first-quarter sales slide

By

US sales fell 10%, and corruption allegations in China ate into emerging-market sales.

Color keeps GSK generic off the market

Color keeps GSK generic off the market

By

GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.

GSK's Breo approved in Europe, COPD market may be underestimated

GSK's Breo approved in Europe, COPD market may be underestimated

By

Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.

GSK adds competitor to COPD market

By

The FDA approved the Breo/Ellipta combo, but analysts are wary about its potential to go beyond the COPD indication in the US.

Email Newsletters